Warfarin Pharmacogenetics Reevaluated:  Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.

Stack, Gary; Maurice, Carleta B

Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials.

Stack, Gary; Maurice, Carleta B.

Afiliação

Stack G; From the Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven; Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT. gary.stack@yale.edu.
Maurice CB; From the Pathology and Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven;

Am J Clin Pathol ; 145(5): 671-86, 2016 May.

Article em En | MEDLINE | ID: mdl-27247371

Assuntos

Algoritmos; Anticoagulantes/administração & dosagem; Varfarina/administração & dosagem; Feminino; Genótipo; Humanos; Masculino; Testes Farmacogenômicos; Estudos Retrospectivos

Palavras-chave

CYP2C9; Dose algorithm; Genotype; Oral anticoagulant; Pharmacogenetics; Subgroup; VKORC1; Warfarin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varfarina / Algoritmos / Anticoagulantes Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Am J Clin Pathol Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google